Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Upgraded by Leerink Partnrs

Kymera Therapeutics (NASDAQ:KYMR) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.93) EPS and Q4 2025 earnings at ($1.00) EPS.

KYMR has been the subject of a number of other reports. Morgan Stanley boosted their price target on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. B. Riley raised their target price on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Finally, Leerink Partners restated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Monday. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.67.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $46.88 on Monday. The firm’s 50 day moving average price is $43.34 and its 200-day moving average price is $38.81. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $50.19. The company has a market cap of $2.88 billion, a PE ratio of -18.68 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The company’s revenue was up 55.2% compared to the same quarter last year. During the same period last year, the business posted ($0.67) EPS. On average, analysts forecast that Kymera Therapeutics will post -2.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Kymera Therapeutics news, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total value of $1,060,272.45. Following the completion of the transaction, the insider now directly owns 95,470 shares of the company’s stock, valued at $4,373,480.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 482,105 shares of company stock valued at $18,651,584. Company insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KYMR. Ameritas Investment Partners Inc. grew its position in shares of Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after purchasing an additional 295 shares during the period. Comerica Bank grew its stake in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares in the last quarter. Keudell Morrison Wealth Management raised its holdings in Kymera Therapeutics by 7.2% in the 2nd quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after acquiring an additional 480 shares during the last quarter. Congress Asset Management Co. MA grew its position in shares of Kymera Therapeutics by 1.2% in the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after purchasing an additional 533 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Kymera Therapeutics by 4.7% in the 1st quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after acquiring an additional 547 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.